Intercure (INCR) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed Intercure (INCR) over the past year, losing 35.8% versus a loss of 37.5%. Over five years, INCR leads with a -85.8% price change compared with -95.9% for PMN. ProMIS Neurosciences is the larger company by market cap ($82.1 million vs $75.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | PMN |
|---|---|---|
| Share price | $5.03 | $9.15 |
| Market cap | $75.47M | $82.05M |
| 1-day change | -1.95% | +0.33% |
| YTD return | +10.55% | +33.97% |
| 1-year return | -37.52% | -35.79% |
| 5-year return | -85.81% | -95.93% |
| EPS (TTM) | $-0.95 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.45 | $27.40 |
| 52-week low | $3.40 | $6.27 |
| Distance from 52-week high | -40.47% | -66.61% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +365.68% |
| Average volume | 21.69K | 84.01K |
| Shares outstanding | 15.00M | 8.97M |
| Employees | 285 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Healthcare · Drug Manufacturers - Specialty & Generic · 285 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Healthcare · Biotechnology · 10 employees
INCR vs PMN FAQ
Which is bigger, Intercure or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $82.05M compared with $75.47M for Intercure (INCR).
Which stock has performed better over the past year, INCR or PMN?
PMN returned -35.79% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and ProMIS Neurosciences in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Intercure and Biotechnology for ProMIS Neurosciences.